Connor, Clark & Lunn Investment Management (CC&L)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$11.3M Buy
1,257,691
+215,267
+21% +$1.93M 0.04% 367
2025
Q1
$7.82M Buy
1,042,424
+408,560
+64% +$3.06M 0.03% 380
2024
Q4
$4.77M Sell
633,864
-48,460
-7% -$364K 0.02% 494
2024
Q3
$5.19M Sell
682,324
-100,340
-13% -$763K 0.03% 422
2024
Q2
$4.84M Buy
782,664
+63,222
+9% +$391K 0.02% 434
2024
Q1
$3.65M Buy
719,442
+27,744
+4% +$141K 0.02% 503
2023
Q4
$4.14M Buy
691,698
+148,922
+27% +$892K 0.02% 480
2023
Q3
$3.84M Buy
542,776
+141,567
+35% +$1M 0.02% 455
2023
Q2
$2.82M Buy
401,209
+53,598
+15% +$377K 0.01% 519
2023
Q1
$2.9M Buy
347,611
+319,815
+1,151% +$2.67M 0.02% 477
2022
Q4
$319K Buy
+27,796
New +$319K ﹤0.01% 972
2022
Q2
Sell
-92,430
Closed -$1.5M 1045
2022
Q1
$1.5M Buy
+92,430
New +$1.5M 0.01% 570
2021
Q3
Sell
-48,352
Closed -$764K 1042
2021
Q2
$764K Buy
+48,352
New +$764K ﹤0.01% 710
2020
Q2
Sell
-611,934
Closed -$1.22M 1015
2020
Q1
$1.22M Buy
611,934
+434,452
+245% +$869K 0.01% 519
2019
Q4
$612K Buy
+177,482
New +$612K ﹤0.01% 630
2018
Q2
Sell
-16,253
Closed -$78K 1031
2018
Q1
$78K Sell
16,253
-21,275
-57% -$102K ﹤0.01% 695
2017
Q4
$184K Sell
37,528
-11,327
-23% -$55.5K ﹤0.01% 726
2017
Q3
$256K Buy
+48,855
New +$256K ﹤0.01% 726
2016
Q3
Sell
-133,005
Closed -$378K 838
2016
Q2
$378K Sell
133,005
-68,568
-34% -$195K ﹤0.01% 637
2016
Q1
$570K Sell
201,573
-5,000
-2% -$14.1K ﹤0.01% 547
2015
Q4
$2.13M Sell
206,573
-31,700
-13% -$327K 0.02% 329
2015
Q3
$2.72M Buy
238,273
+147,775
+163% +$1.68M 0.02% 261
2015
Q2
$1.35M Sell
90,498
-70,100
-44% -$1.05M 0.01% 292
2015
Q1
$1.45M Sell
160,598
-52,500
-25% -$474K 0.01% 265
2014
Q4
$2.59M Buy
213,098
+43,700
+26% +$531K 0.02% 207
2014
Q3
$1.66M Buy
169,398
+20,000
+13% +$196K 0.01% 233
2014
Q2
$2.03M Sell
149,398
-378,700
-72% -$5.14M 0.01% 245
2014
Q1
$6.17M Buy
528,098
+211,220
+67% +$2.47M 0.05% 146
2013
Q4
$2.56M Buy
+316,878
New +$2.56M 0.02% 231
2013
Q3
Sell
-111,800
Closed -$183K 527
2013
Q2
$183K Buy
+111,800
New +$183K ﹤0.01% 477